TransEnterix Inc (TRXC) Jumps 9.61% on December 25

Equities Staff |

TransEnterix Inc (TRXC) was among the biggest gainers on the Russell 2000 for Friday December 25 as the stock popped 9.61% to $2.51, representing a gain of $0.22 per share. Some 546,549 shares traded hands on 1,673 trades, compared with an average daily volume of 344,558 shares out of a total float of 100.14 million. The stock opened at $2.31 and traded with an intraday range of $2.60 to $2.26.

After today's gains, TransEnterix Inc reached a market cap of $251.36 million. TransEnterix Inc has had a trading range between $4.87 and $2.07 over the last year, and it had a 50-day SMA of $2.51 and a 200-day SMA of $2.96.

TransEnterix Inc is a medical device company engaged in the development and commercialization of a robotic assisted surgical system called the SurgiBot System.

TransEnterix Inc is based out of Morrisville, NC and has some 100 employees. Its CEO is Todd M. Pope.

For a complete fundamental analysis analysis of TransEnterix Inc, check out Equities.com’s Stock Valuation Analysis report for TRXC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…